Cancer pain management integrates systemic analgesics, nerve blocks, and supportive therapies to control cancer-related physical discomfort. According to the World Health Organization (WHO 2018) guidelines and National Comprehensive Cancer Network (NCCN 2024) recommendations, effective pain control is achievable in up to 90% of patients through standardized assessment protocols and individualized treatment planning. Management spans the entire continuum of cancer care, from diagnosis through active treatment, survivorship, and advanced disease.

Cancer pain management begins with detailed diagnostic mapping, evaluating pain intensity, anatomical site, and neurophysiological character. Pharmacological protocols initiate systemic analgesics titrated to clinical response. Interventional procedures, when indicated, are performed under real-time fluoroscopic or computed tomography (CT) guidance using local anaesthesia or moderate sedation. Regional neurolysis utilizes agents such as dehydrated alcohol or phenol to interrupt pain signals permanently or semi-permanently along targeted nerve pathways.

Evidence-based cancer pain management provides significant clinical advantages:

• Symptom control: High rates of pain intensity reduction when protocols follow established guidelines (WHO 2018, NCCN 2024).
• Functional preservation: Enhanced mobility, improved sleep hygiene, and reduced metabolic exhaustion.
• Treatment continuity: Reduced need to delay or discontinue cancer-directed treatments due to unmanaged physical distress.
• Targeted interventional options: Significant reduction in systemic opioid requirements following regional nerve neurolysis (Bennett et al., 2012).

Recovery and response timelines vary by therapeutic modality. Oral opioid titration typically produces functional analgesia within 24 to 72 hours. Interventional nerve blocks, such as a celiac plexus neurolysis, often yield immediate pain relief within 12 to 24 hours. Patients receiving palliative radiotherapy for painful bone metastases generally experience maximum analgesic effect within 2 to 4 weeks following treatment completion (DEGRO guidelines, 2018). Ongoing clinical adjustments ensure sustained pain control across all disease stages.

Cancer pain management addresses multiple pain syndromes associated with malignancy and oncological treatment:

• Somatic nociceptive pain: Bone metastases, soft tissue invasion, and post-surgical wound pain.
• Visceral nociceptive pain: Capsular stretch of liver metastases, bowel obstruction, and pancreatic tumor infiltration.
• Neuropathic pain: Chemotherapy-induced peripheral neuropathy (CIPN), post-radiation plexopathy, tumor nerve compression, and post-mastectomy pain syndrome.
• Breakthrough pain: Transient flares of severe pain that erupt over controlled baseline pain.

Preparation involves comprehensive medical history review, baseline blood chemistry analysis, and evaluation of coagulation profiles (Platelets > 50,000/mcL, INR < 1.5 for neuraxial or deep interventional blocks). Patients taking anticoagulant or antiplatelet medications undergo structured pre-procedure cessation protocols under specialist supervision. Imaging studies, including magnetic resonance imaging (MRI) or CT scans, are reviewed to verify anatomical access routes.

Pharmacological risks include opioid-induced constipation, nausea, sedation, respiratory depression, and neurotoxicity (myoclonus, hyperalgesia). Interventional risks include local hematoma formation, localized infection, transient hypotension following visceral nerve block, nerve injury, dura mater perforation, and incomplete analgesia requiring secondary procedures.

The clinical journey begins with a comprehensive pain assessment evaluating intensity, functional impact, and underlying pain etiology. Clinicians establish baseline scores using standardized tools such as the Numerical Rating Scale (NRS) or Brief Pain Inventory (BPI). Initial treatment typically utilizes non-opioid or opioid pharmacotherapy guided by the WHO analgesic ladder. For complex or refractory pain, clinicians escalate therapy to interventional procedures, such as celiac plexus block or intrathecal drug delivery systems (ITDDS), accompanied by ongoing reassessment and dose titration.